摘要
目的评价国内溴隐亭治疗垂体催乳素瘤的疗效和安全性。方法搜集国内溴隐亭与经蝶窦入路显微手术治疗催乳素瘤的病例对照试验文献，对符合纳入标准的研究使用统计软件RevMan5．1．0完成荟萃分析。结果共纳入8篇回顾性对比分析文献研究，总计1559例患者，平均随访时间6个月以上，利用随机效应模型进行荟萃分析，与经蝶窦入路显微手术组相比，溴隐亭组降低催乳素（PRL）分泌有效率的合并OR=0．80（95％CI：0．38～1．67），P=0．55，不良反应发生率的合并OR=3．70（95％CI：0．61～22．29），P=0．15。结论国内的有限证据表明，与经蝶窦入路显微手术相比，口服溴隐亭在降低催乳素瘤患者血PRL水平和不良反应发生率方面差异没有统计学意义。
Objective To evaluate the effectiveness and safety of bromocriptine on treating prolactinoma in China. Methods Case - controlled trials of bromocriptine on treating prolactinoma in China were collected, and systematic review and Meta - Analysis were conducted. Results A total of 8 case -control trials involving 1559 patients were included, and the average follow -up time was more than 6 months. As for the total effective rate and the incidence of side effects, no significant differences were found between bromocriptine and transsphenoidal microsurgery （ OR = 0. 80,95% CI： 0. 38 - 1.67, P = 0. 55 ） or （ OR = 3.70,95% CI： 0. 61 - 22.29, P = 0. 15 ）, respectively. Conclusion Observational evidence supports that treatments of prolactinoma using bromocriptine compared to transsphenoidal microsurgery in China have no difference regarding the effective rate and the incidence of side effects.
出处
《中华神经外科杂志》
CSCD
北大核心
2012年第9期918-922,共5页
Chinese Journal of Neurosurgery
基金
北京市自然科学基金资助项目（基金编号7102028）
北京市卫生系统高层次卫生技术人员培养计划（2009-3-23）
